Stefano Fanti: Thank you, Amber. Good morning everybody. Great pleasure to be here again. Thanks to Aurelius and Silke for the amazing job that they did over the last year. Really incredible. Those are my disclosures, as you can see are many. The main disclosures that I’m proudly a nuclear medicine physician, so I’m strongly […]
Alicia Morgans: Hi, I’m thrilled to have here with me today Dr. Colin Pritchard, who is an Associate Professor of Laboratory Medicine at the University of Washington, and we’re talking at APCCC 2019, where we just heard a lovely talk from you about molecular characterization of our tumors, specifically thinking about genomics and genetics. And […]
This Australian study is the largest published experience of the use of Ga68 PSMA PET/CT imaging in the context of previous primary radiotherapy for prostate cancer. This study evaluated 276 men who had undergone a Ga68 PSMA PET/CT for which the majority had PSA biochemical failure (mean PSA 3.60 ng/mL, range 0.01–83 ng/mL). Overall, 86% (239/276) men had […]
The Future of CDK4/6 Inhibitors for Prostate Cancer May Need to Draw Inspiration from Goldilocks and the Three Bears — Cyclin dependent kinases (CDKs) and D-type cyclins (CCND) have a critical role in cell cycle progression from G1 to S phase.1 Several tumors have been shown to have alterations of proteins involved in the activity and […]
Renal Mass Registry Condition: Renal Cell Carcinoma Intervention: Other: questionnaire Purpose: Collect valuable risk factor and quality of life data from Renal Cell Carcinoma patients and harness the latest technology to organize and analyze data. Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT01887574 Sponsor: Mayo Clinic Primary Outcome Measures: Measure: Evidence of Renal Mass […]
Tumor regression grades (TRGs) quantify the pathologic response to neoadjuvant chemotherapy (NAC). The aim of the study was to investigate the prognostic value of TRGs in combination with the TNM classification in an independent cohort of patients with muscle-invasive bladder cancer (MIBC) treated with NAC followed by radical cystectomy (RC) in a retrospective setting. Patients […]
The role of a thorough pelvic lymph node dissection at radical cystectomy for high risk bladder cancer is an important component for quality surgical care. Selected patients with advanced disease involving the retroperitoneal lymph nodes (limited nodal disease, significant response to systemic therapy, and the ability to resect all sites of prior involvement) may benefit […]
Aim: To evaluate the role of preoperative platelet distribution width (PDW) as a potential biomarker for distinguishing malignancy and tumor advantage of bladder neoplasm. Methods: The study included 210 subjects with bladder cancer, 76 subjects with urothelial papilloma and 132 healthy control subjects. Preoperative PDW along with other blood indices was evaluated. Results: PDW was […]
Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of cancer related death in men in Western countries. The standard therapy for metastatic PCa is androgen suppression therapy (AST). Men undergoing AST eventually develop metastatic castration-resistant prostate cancer (mCRPC), of which there are limited treatment options available. Immunotherapy has […]
Brachytherapy (BT) is widely used for salvage therapy in patients with biochemical failure (BF) after radiotherapy for prostate cancer (PCa). Although low-dose-rate (LDR) and high-dose-rate (HDR) BT are both used for salvage therapy, it is not clear whether there are any differences between these two approaches in terms of efficacy or toxicity in this setting. […]
